Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zimny, M.
Right arrow Articles by Buell, U.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Zimny, M.
Right arrow Articles by Buell, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 10:S28-S32, 1999
© 1999 European Society for Medical Oncology

Review

18FDG-positron emission tomography in pancreatic cancer

Michael Zimny and Udalrich Buell

Department of Nuclear Medicine, University Hospital, Aachen University of Technology Germany

Correspondence to: Michael Zimny, Department of Nuclear Medicine, University Hospital, Aachen University of Technology, Pauwelsstraße 30, D-52074 Aachen, Germany, email: zimny{at}nuk-gate.nukmed.rwth-aachen.de

Positron emission tomography: Malignant cells present an increased glucose consumption compared to normal pancreatic tissue. Positron emission tomography with 18F fluoro - D-deoxyglucose is a new imaging tool to in vivo assess the amount of glucose metabolism. This method provides metabolic information on tumors rather than morphological information.

Methods: In most PET centers a static emission scan of the upper abdomen is performed 45 – 60 minutes after intravenous administration of the radiotracer. To obtain quantitative parameter an additional transmission scan is necessary to correct for attenuation. Today, both visual analysis and semiquantitative parameters of glucose consumption as the Standardized Uptake Value (SUV) are used for image interpretation. To allow coregistration of the metabolic PET images and morphological imaging tools as CT or MRI external markers may be used. Following exact reorientation both the metabolic information (PET) and the morphologic information (MRI/CT) can be merged in one 3D data set (image fusion).

Results: In our series of patients the sensitivity for PET to detect pancreatic cancer was 85%, the specificity 84%. False negative results were obtained in patients with hyperglycemia, false positive results in patients with chronic active pancreatitis. Excluding hyperglycemic patients the sensitivity for PET increased to 98%. In a sample statistics of 305 euglycemic patients sensitivity, specificity and accuracy were 92%, 79%, and 87%, respectively.

Image fusion of metabolic (PET) and morphologic data (MRI/CT) can help to better localize the focus of increased glucose consumption demonstrated with PET and to differentiate multifocal cancer from lymph node metastases.

Conclusion: 18FDG PET is a feasible diagnostic modality to differentiate benign and malignant pancreatic masses when morphological imaging is equivocal. Image fusion of PET and CT or MRI can combine the advantages of both modalities in one image - detailed anatomic information combined with accurate metabolic data.

FDG, pancreatic carcinoma, positron emission tomography


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.